BioWorld

Dec. 23, 2004

View Archived Issues

Neurochem Signs Potential $54M Deal With Centocor For Fibrillex

Just a few weeks after completing the treatment portion of a Phase II/III trial of Fibrillex, Neurochem Inc. partnered its AA amyloidosis drug with Centocor Inc. in a deal worth up to $54 million. (BioWorld Today) Read More

Isis Sells Macugen Royalties: $24M To Push Pipeline Drugs

Read More

Symbollon Beginning Phase III With Product For Breast Pain

Read More

Creative Thinking Required For Debate Over Follow-On Biologics

Read More

Correction

Read More

Other News To Note

Read More

Appointments And Advancements

Read More